PURPOSE
Uncommon epidermal growth factor receptor (EGFR) mutations account for ∼10% of EGFR-altered non-small cell lung cancer (NSCLC) and show heterogeneous sensitivity to EGFR-tyrosine kinase inhibitors (TKIs), with limited prospective evidence to inform first-line therapy. Sutetinib is an irreversible EGFR-TKI. We a...
Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al.· Journal of Thoracic Oncology· 0 citations
Lung cancer brain metastasis (LCBM) is a major cause of cancer-related mortality, driven by the restrictive blood–brain barrier (BBB), an immunosuppressive microenvironment, and dynamic metabolic reprogramming. Increasing evidence suggests that LCBM is governed by coordinated interactions among neural, immune, and vasc...
Jiaojiao Li, Mingjun Xu, Lei Wang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.